valueforme Posted - 3 days ago

$CLSD 👇From last week's $AURA status updates call. Safety profile of suprachoroidal injections is underestimated

Stocksrunner Posted - 1 week ago

Analysts are bullish on $AURA $CSBR $FSLR $KIM are you ready for the potential gains? 📈 Check your portfolio and stay ahead of the curve! https://stocksrunner.com/posts/1135

Freddie___Mac Posted - 1 week ago

$AURA very promising data. Stock is very undervalued. Positive bladder data next month will expand the applicability of bel-sar

BioTuesdays Posted - 1 week ago

Aura Biosciences has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a life-threatening ocular cancer $AURA https://biotuesdays.com/2024/09/12/aura-announces-positive-phase-2-eos-results-evaluating-bel-sar-for-cm/

inbest Posted - 1 week ago

@Harvo I agree when it comes to the prospect of losing vision. However, when the prospect is dying from cancer, 95% vs 80% will still make a difference to many patients. However, $AURA's approach is innovative, and their P2 results are very good, so I am bullish and looking forward to their P3 study

Harvo Posted - 1 week ago

$AURA Upon approval, Belsar will always come before radio therapy. Blindness is one of the scariest propositions to the human mind.

inbest Posted - 1 week ago

$AURA In summary ( and imho, of course ) a very promising program they are developing; definitely worth the investment for everyone who in principle would invest in the oncology space.

inbest Posted - 1 week ago

$AURA The P2 patient who lost vision lost it due to fluid emanating from the tumor, the tumor itself was controlled. Imho, this makes it a non-failure. They are really doing a good job, I think.

inbest Posted - 1 week ago

$AURA The discussion boils down to have a slightly lower tumor control (with 80% it is still high imho, radiotherapy has 85%) vs. prevention of vision loss, which, as i understand it, would *always* ensue with radiotherapy of the fast-growing tumors they address. Personally, I don't know how whether I'd opt to keep my vision - you never know before being in the situation. But I think it is a viable option, even more so for tumors that grow slowly.

OpenOutcrier Posted - 1 week ago

$AURA (+7.5% pre) Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - Stock Titan https://ooc.bz/l/42193

briefingcom Posted - 1 week ago

$AURA: Aura Biosciences reports positive Phase 2 end of study results evaluating Bel-sar as a first-line treatment for early-stage Choroidal Melanoma

tradingtwenty Posted - 1 week ago

$AURA has trended 15 times in the past 24 hours (based on 5 minute intervals). Latest press release on Sep 12, 2024 06:30 AM: Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for.. Link: https://tradingtwenty.com/news/619786/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-first-line-treatment-for-early-stage-choroidal-melanoma

Harlaxton Posted - 1 week ago

$AURA loaded the boat almost a year ago. Looks like it might be a good investment after all.

inbest Posted - 1 week ago

$AURA No vision loss as opposed to radiotherapy of tumors, especially of tumors close to the optic nerve/fovea (center of retina where vision is most acute). While keeping in mind this is a company presentation, it still sounds really impressive,

inbest Posted - 1 week ago

$AURA Impressive safety profile, especially when contrasted with radiotherapy

briefingcom Posted - 1 week ago

Gapping up: $NTGR +23% $SIG +14.7% $AURA +7.5% $BTG +4.7%

DonCorleone77 Posted - 1 week ago

$AURA Aura Bioscience's bel-sar shows positive Phase 2 results in melanoma study Aura Biosciences announced positive Phase 2 end of study results evaluating bel-sar for the first-line treatment of early-stage choroidal melanoma - CM -, a vision and life-threatening ocular cancer. Phase 2 results demonstrated that bel-sar achieved an 80% tumor control rate among Phase 3-eligible patients who received the therapeutic regimen, with complete cessation of growth following treatment among responders. Visual acuity preservation was achieved in 90% of these 10 patients. Importantly, 80% of these 10 patients were at high risk for vision loss with tumors close to the fovea or optic disc, highlighting the potential for vision preservation with this novel class of drugs. Phase 2 results are a significant achievement considering the typically poor prognosis associated with choroidal melanoma. The safety profile of bel-sar was highly favorable in all participants regardless of dose. There were no treatment-related serious adverse events reported. Aura received written agreement from the FDA under a Special Protocol Assessment for the design and planned analysis of the global Phase 3 CoMpass trial indicating concurrence by the FDA with the adequacy of the study, if successful, to address the objectives necessary to support Aura's planned biologics license application submission.

Charlestrader777 Posted - 1 week ago

$AURA solid news 👀👀👀

inbest Posted - 1 week ago

$AURA From the press release: >>> Bel-sar has the potential to become the first treatment that achieves the dual goals of treating the tumor while also preserving vision, which could change the treatment paradigm for patients with this disease. <<< I love it!

Stock_Titan Posted - 1 week ago

$AURA Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma https://www.stocktitan.net/news/AURA/aura-biosciences-reports-positive-phase-2-end-of-study-results-8ofqf8wlz8zx.html

Stock_Titan Posted - 2 weeks ago

$AURA Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 https://www.stocktitan.net/news/AURA/aura-biosciences-to-host-a-urologic-oncology-investor-event-to-1mxzr3epfg1d.html

justiceforb_85 Posted - 08/27/24

$AURA #XBI looking forward to upcoming data on bel-sar in choroidal melanoma. https://ir.aurabiosciences.com/news-releases/news-release-details/aura-biosciences-announces-presentation-phase-2-end-study-data

Sstanley14 Posted - 08/27/24

$AURA is this halted??

Stock_Titan Posted - 08/26/24

$AURA Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting https://www.stocktitan.net/news/AURA/aura-biosciences-announces-the-presentation-of-phase-2-end-of-study-pt175qzk33rp.html

insidemoney Posted - 08/21/24

Unusual Stock Volume (Aug 20) $VVOS Vivos Therapeutics Volume 345,826 Average 61,251 (x 6) $VIOT Viomi Technology Volume 344,174 Average 176,045 (x 2) Earnings 26-Aug-2024 BMO $AURA Aura Biosciences Volume 342,556 Average 171,850 (x 2)

Sillyspuh Posted - 1 month ago

$AURA sometimes it feels like these small cap biotech stocks are cleverly disguised EKG tests

Sillyspuh Posted - 1 month ago

$AURA this drop surprises me. When will they bounce?

Goosem4n Posted - 1 month ago

$AURA 👀

G101SPM Posted - 1 month ago

$AURA $8.20 ask. BUY/NEW LONG POSITION carries SPM 87.71 tag to $11.00 as first level in midterm.

OogwayTradez Posted - 1 month ago

$SOL.X Check out aura/SOL on DEX Screener! https://dexscreener.com/solana/9ViX1VductEoC2wERTSp2TuDxXPwAf69aeET8ENPJpsN $aura on Solana